Zydus Lifesciences (ZYDUSLIFE) | Stock Overview & Key Data
Zydus Lifesciences Performance Comparison
Stock Range
Today's Range
Low: ₹932.10
High: ₹949.75
on August 8, 2025
52 Week Range
Low: ₹795.00
High: ₹1,324.30
on April 7, 2025
on August 9, 2024
All-Time High: ₹1,324.30 on August 5, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR964.8B
EPS
44.98
P/E Ratio (TTM)
21.32
Forward P/E
22.21
P/B Ratio
4.03
PEG Ratio
1.19
Div. Yield
1.44%
ROE
19.28%
Beta
0.459
Debt to Equity
12.21
Financial Highlights
Profitability
Gross Margin
73.02%
Operating Margin
29.23%
Profit Margin
19.47%
Returns and Earnings
Return on Assets (TTM)
11.21%
Return on Equity (TTM)
19.28%
EBITDA
INR71.9B
Net Income (TTM)
INR45.3B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR230.98
Quarterly Revenue Growth (YoY)
18.00%
Quarterly Earnings Growth (YoY)
-1.00%
Dividend Information
Last 12-Month Dividend
₹14.00
Current Dividend Yield
1.44%
3-Year Average Dividend Yield
0.79%
3-Year Average Annual Dividend
₹9.50
3-Year Total Dividends
₹28.50
Ex-Dividend Date
July 25, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Zydus Lifesciences ZYDUSLIFE | 964.82B Large-cap | -2.61% | -5.44% | 6.58% | -5.00% | -3.01% | -28.30% | 141.10% | 135.86% |
| Sun Pharmaceutical SUNPHARMA | 3.92T Large-cap | -6.35% | -4.85% | -10.27% | -8.65% | -15.43% | -8.07% | 74.63% | 200.22% |
| Divi's Laboratories DIVISLAB | 1.63T Large-cap | -7.04% | -10.99% | -0.27% | -0.15% | 0.96% | 26.95% | 64.55% | 98.44% |
| Cipla CIPLA | 1.20T Large-cap | -4.09% | -1.29% | -1.18% | 1.27% | 0.78% | 3.58% | 45.16% | 93.18% |
| Torrent TORNTPHARM | 1.22T Large-cap | -3.88% | 7.29% | 9.29% | 10.38% | 5.21% | 5.56% | 128.85% | 24.13% |
| Mankind Pharma MANKIND | 1.08T Large-cap | -1.15% | 5.29% | 4.33% | 0.76% | -11.91% | 19.66% | 83.31% | 83.31% |
Ownership & Short Interest
Insider Ownership
75.15%
Institutional Ownership
13.80%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
896K
Average 90-Day Volume
908K
Zydus Lifesciences Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Zydus Lifesciences would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ZYDUSLIFE's 52-week high and low?
- In the last 52 weeks, Zydus Lifesciences reached a high of ₹1,324.30 (on August 9, 2024) and a low of ₹795.00 (on April 7, 2025).
- What is the market cap and P/E ratio for ZYDUSLIFE?
- Curious about Zydus Lifesciences's size and valuation? Its market capitalization stands at 964.82B. When it comes to valuation, the P/E ratio (trailing twelve months) is 21.32, and the forward P/E (looking ahead) is 22.21.
- Does ZYDUSLIFE pay dividends? If so, what's the yield?
- Yes, Zydus Lifesciences is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 1.44%, and the company has paid an average of ₹9.50 per share annually over the past 3 years.
- Who are Zydus Lifesciences's main competitors or similar companies to consider before investing?
When looking at Zydus Lifesciences, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.92T Healthcare Drug Manufacturers - Specialty & Generic -8.07% 74.63% Divi's Laboratories
DIVISLAB1.63T Healthcare Drug Manufacturers - Specialty & Generic 26.95% 64.55% Cipla
CIPLA1.20T Healthcare Drug Manufacturers - Specialty & Generic 3.58% 45.16% Torrent
TORNTPHARM1.22T Healthcare Drug Manufacturers - Specialty & Generic 5.56% 128.85% Mankind Pharma
MANKIND1.08T Healthcare Drug Manufacturers - Specialty & Generic 19.66% 83.31% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Zydus Lifesciences Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Zydus Lifesciences's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 19.28%, the Debt to Equity ratio from the most recent quarter is 12.21, and its Gross Profit Margin stands at 73.02%.
- What is the recent revenue and earnings growth for ZYDUSLIFE?
- Looking at Zydus Lifesciences's growth, its revenue over the trailing twelve months (TTM) was INR232B. Compared to the same quarter last year (YoY), quarterly revenue grew by 18.00%, and quarterly earnings saw a YoY growth of -1.00%.
- How much of ZYDUSLIFE stock is held by insiders and institutions?
- Wondering who owns Zydus Lifesciences stock? Company insiders (like executives and directors) hold about 75.15% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 13.80%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.